Skip to content

Reward-related neural activity after low doses of LSD in participants with depressed mood.

James Glazer, Hanna Molla, Royce Lee, Robin Nusslock, Harriet de Wit

Journal of psychopharmacology (Oxford, England) January 13, 2026 DOI: 10.1177/02698811251405686 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 39
Population Adults with subclinical mild-to-moderate depression (N=20) and controls with minimal symptoms (N=19)
Intervention LSD
Dose 26 μg tartrate
Duration Two sessions; 48-hour follow-up
Topics Depression LSD
Keywords EEG Erp Mood Reward
Key findings LSD increased LPP amplitude to loss feedback only in participants with higher baseline depressed mood, and this effect was associated with acute positive mood and lower depressed mood 48 hours later.

Abstract

Lysergic acid diethylamide (LSD) has been considered as a potential treatment for depression for over 75 years, but its therapeutic potential has only recently been considered in mainstream psychiatry. Repeated ingestion of low doses of LSD ("microdoses") is thought to reduce depression, but the neurobiology underlying this effect is unknown. We previously reported that low doses of LSD increased event-related potentials (ERPs) during receipt of monetary rewards in healthy adults. LSD also produced more positive subjective effects in participants with mild-to-moderate baseline symptoms of depressed mood, compared to controls. In this report, we examined the effects of LSD on reward ERPs in participants with mild-to-moderate depressed mood and in non-depressed controls. Participants with subclinical mild-to-moderate depression (N = 20) or controls with minimal symptoms (N = 19) received LSD (26 μg tartrate) or placebo on two sessions. Primary measures were ERPs during a reward task, and secondary measures included self-reported mood during and 48 hours after the sessions. LSD (vs placebo) increased late positive potential (LPP) amplitude to loss (vs win) reward feedback only in participants with higher baseline depressed mood, suggesting enhanced affective processing given the role of LPP in emotional valuation of reward. This effect of LSD on LPP was associated with its acute positive mood effects, and with lower depressed mood 48-hour after the LSD (vs placebo) session. In the full sample, LSD (vs placebo) decreased feedback-P3 and LPP amplitude to reward (vs neutral) feedback. Although findings must be interpreted with caution, results support the idea that low doses of LSD have potential anti-depressant effects.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Low-dose LSD increased late positive potential amplitude to loss feedback in participants with higher baseline depressed mood, and this effect was associated with lower depressed mood 48 hours later.

    Synthesized

Comparable studies

Other randomized controlled trials on LSD for depression, most cited first.

Study Year Design Participants
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Patients who experienced anxiety with or without association with a life-threatening... 2023 Randomized controlled trial n = 42
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. Patients with anxiety with or without life-threatening illness 2024 Randomized controlled trial n = 39
Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Patients with moderate-to-severe major depressive disorder 2025 Randomized controlled trial n = 61
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder. Patients meeting DSM-5 criteria for major depressive disorder 2024 Randomized controlled trial
Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment Patients with major depressive disorder (MDD) 2026 Randomized controlled trial n = 35

Explore topics

By condition and practice